The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care–updates at the 2023 plenary event
P Zaratin, S Samadzadeh, M Seferoğlu… - Frontiers in …, 2024 - frontiersin.org
Significant advancements have been achieved in delineating the progress of the Global
PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the …
PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the …
Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms
KA Jellinger - Journal of Neural Transmission, 2024 - Springer
Multiple sclerosis (MS) is an autoimmune-mediated disease of the central nervous system
characterized by inflammation, demyelination and chronic progressive neurodegeneration …
characterized by inflammation, demyelination and chronic progressive neurodegeneration …
[PDF][PDF] Yolanda Aladro, European University of Madrid, Spain
LL Pascual, IR Zarbo, P Zaratin, P Zaratin… - 2024 - researchgate.net
The global Patient Reported Outcome for Multiple Sclerosis (PROMS) Initiative 1 was
inaugurated on 12 September 2019 at the 35th Congress of the European Committee for …
inaugurated on 12 September 2019 at the 35th Congress of the European Committee for …
[HTML][HTML] Cognitive assessment in the early stages of multiple sclerosis: the importance of screening and management of cognitive impairment
ED Skorve - 2024 - bora.uib.no
Background: Cognitive impairment (CI) is a common symptom in patients with multiple
sclerosis (MS) with a potentially large impact on quality of life, employment, and social life. It …
sclerosis (MS) with a potentially large impact on quality of life, employment, and social life. It …
Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study
K Kania, MA Pawlak, M Forycka… - Neurologia i …, 2024 - journals.viamedica.pl
Introduction. Cognitive impairment occurs from the earliest stages of multiple sclerosis (MS)
and progresses over time. The introduction of disease modifying therapies (DMTs) has …
and progresses over time. The introduction of disease modifying therapies (DMTs) has …